Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial

Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga-Morskaya, Abigail Liebow, Brian R. Bettencourt, Jessica E. Sutherland, Renta M. Hutabarat, Valerie A. Clausen, Verena Karsten, Jeffrey Cehelsky, Saraswathy V. Nochur, Victor Kotelianski, Jay Horton, Timothy Mant, Joseph Chiesa, James Ritter, Malathy Munisamy, Akshay K. Vaishnaw, Jared A. Gollob, Amy Simon

Research output: Contribution to journal › Article › peer-review

486 Scopus citations

Fingerprint

Dive into the research topics of 'Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial'. Together they form a unique fingerprint.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial

Fingerprint

Medicine & Life Sciences